|Bid||11.85 x 1000|
|Ask||11.88 x 800|
|Day's Range||11.82 - 12.12|
|52 Week Range||9.13 - 15.86|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for DNALearn more
BOSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Block & Leviton announces that a class action lawsuit has been filed against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities law violations. Investors who purchased shares and have lost money are encouraged to contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/dna. What is this all about? On October 6, 2021, short seller Scorpion Capital released a repor
NEW YORK, NY / ACCESSWIRE / December 1, 2021 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Ginkgo Bioworks Holdings Inc. ("Ginkgo" or the "Company") (NYSE:DNA; SRNG) (f/k/a Soaring Eagle Acquisition Corp.
LOS ANGELES, CA / ACCESSWIRE / December 1, 2021 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp.